Please login to order a test.
Hepatitis C Virus (HCV) Antibody Verification
Since as many as 90% of commercial intravenous immunoglobulins test positive for hepatitis C antibody, an artifactual positive can result briefly after transfusion. Following the development of sensitive and specific testing for hepatitis B, 90% of post-transfusion hepatitis is now hepatitis C. A gene product (c100) of hepatitis C virus (HCV) was isolated and an assay for anti-HCV developed. The assay detects antibody to presumptive togavirus, which may be an etiologic agent of non-A, non-B hepatitis (which may not be a unitary disease entity).
Testing for HCV antibodies is to assess past or present exposure to hepatitis C virus infection; additional testing for the hepatitis virus is required to determine acute or active infection.
Serum or plasma
0.5 mL (Note: This volume does not allow for repeat testing.)
If tube other than a gel-barrier tube is used, transfer separated serum or plasma to a plastic transport tube.
Causes for Rejection
Non-EDTA plasma specimen; PST gel-barrier tube
This assay is offered to provide verification of a positive HCV antibody screen obtained using the Siemens Advia Centaur HCV assay or other reagent with comparable sensitivity and specificity. Because the verification methodology is Roche ECLIA, this assay cannot be used to verify an initial screen performed with the Roche methodology.
This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|144090||HCV Antibody Verification||13955-0||144091||HCV Antibody Verification||13955-0|